Lifeline Biotechnologies Inc.

(Public, PINK:LLBO)

With the recent gains in Hard to Treat Diseases Inc. (PINK:HTDS) and BioElectronics Corp. (OTC:BIEL), investors were left hungry for more undervalued, high potential biotech companies — Then came LifeLine Biotechnologies Inc (OTC:LLBO). As technology continues to redefine the modern era of medical advancements, certain companies will stand apart from the rest, as is the case with Lifeline Biotechnologies Inc. This company is an innovative medical technology company committed to the improvement of the quality of life through exceptional health care systems, focusing on prevention, early diagnosis, and quick recovery. Recently, the company has made headlines with their innovative Breast Cancer detection system, the First Warning System ™, a dynamic test which collects information over time with an uncanny efficacy. The next several months will prove to be critical for LifeLine Biotechnologies, as they await the FDA’s decision

...

Companies featured in this edition of the newsletter: CUR, CVM, ENZ, IMUC, MBCI, ONEZ, PHC, SVUL

Markets finished in positive territory yet again during this holiday shortened week despite the lack of any significant developments on either the corporate or economic fronts. All told, the Dow gained 164 points to close at 9605, up 1.7% on the week and 9.4% on the year. The Nasdaq gained 3.1% on the week, closing at 2080, up 32% on the year, while the S&P 500 and Russell 2000 gained 2.6% and 4.0% respectively on the week, up 15.4% and 18.8% on the year.

It was a slow week on the corporate side, but there were some healthy signals from the technology sector, as Texas Instruments raised its Q3 outlook, guiding for EPS of between $0.37 and $0.41, up from previous forecasts of $0.29-$0.39. Fed Ex also guided higher, citing cost management and better

...

Micron Enviro Systems, Inc. (OTCBB: MSVS) (FRANKFURT: NDDA) (”Micron”) has now been assigned a new symbol, which is MSVS. Micron has now commenced trading under the new symbol MSVS and no longer trades under the old symbols of MENV, MENVE or MSVSE. All shareholders will be entitled to receive the forward split shares upon surrender of their common shares. For shareholder who hold their shares through a brokerage house, they should contact their brokerage house directly for information on how the forward split will impact them.

The U.S. Food and Drug Administration (FDA) today cleared the OVA1(TM) Test, the first blood test that, prior to surgery, can help physicians determine if a woman is at risk for a malignant pelvic mass. OVA1 is the first FDA-cleared laboratory test that can indicate the likelihood of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even if radiological test results fail

...

ImmunoCellular Therapeutics, Ltd., a Los Angeles-based clinical-stage company that is developing immune based therapies for the treatment of brain and other cancers, recently announced that the company has entered into a research and license option agreement regarding its ICT-69 antibody with Roche Group (SWX: ROG.VX; RO.S, OTCQX: RHHBY). As one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics, Roche Group will pay royalties to ImmunoCellular Therapeutics based on the company’s worldwide sales of ICT-69 products.

Under the terms of the agreement, ImmunoCellular Therapeutics will license to Roche the rights to investigate the potential of ICT-69 in the diagnosis and treatment of multiple myeloma and ovarian cancer. ICT-69 is one of several monoclonal antibodies currently being developed for multiple cancer indications by ImmunoCellular Therapeutics. Following the evaluation period, Roche has the right to acquire for an option exercise payment a commercial license for ICT-69 from

...

Companies featured in this edition of the newsletter: CBAI, ICLK, ITUI, IWEB, MBCI, OMCM, SIHI, SRCO

Markets continued their torrid pace this week on the strength of encouraging reports from two of the most beleaguered economic sectors, which led to gains in all of the major indices following the week’s activities. All told, the Dow ended the week up 2.2%, gaining 198 to close at 9370, bringing its YTD gains to 6.8%. The Nasdaq gained 1.1% on the week, bringing its yearly gains to 26.8% while the S&P 500 and Russell 2000 posted gains of 2.3% and 2.28 % respectively, bringing their yearly gains to 11.9% and 14.6%.

Economic news stole the spotlight this week as earnings season wound down, leaving investors with a more definitive picture of the overall state of recovery than in many weeks prior. The good news started early in the week, as the ISM

...

We are pleased with the second quarter results of Sunesis Pharma (SNSS). The company recorded revenues of $3.5 million, an increase of 36% over the same period last year. The company does not have any FDA approved product, hence it derives its revenues primarily from collaboration and license agreements.

Though revenues recorded a healthy growth, Sunesis reported net loss of $49.2 million (per share $1.43), compared to a net loss of $13.6 million (per share $0.39) for the year-ago period. This is way below the Zacks Consensus Estimate for per share loss of $0.16. This includes “deemed distribution to preferred stockholders" of $26.4 million. Net income would have been on the higher side, but for the non-cash charges of $21 million related to the private placement.

Loss from operations (without considering extra-ordinary items) for the quarter was at $1.9 million compared to net loss of $8.7 million in the year-ago period.

...

Since I last wrote about Access Pharma [ACCP: 0.00, N/A (N/A)] two weeks ago as a cancer biotech call option trade, the Company has issued two updates on its clinical development pipeline and two updates for MuGard – which is an oral rinse product for the management of a common side effect of many cancer therapies, mucositis. In late May, Access announced that MuGard was launched in Germany, Italy, UK, Greece, and the Nordic countries by its European commercial partner, SpePharm, with expected launches in North America, Asia, and other regions slated for later this year. On 6/10/09, ACCP.OB also announced that the Company received issue notifications from the United States Patent and Trademark Office for two US patents (numbers 7,544,348 and 7,547,433).

A video presentation is available at ProActiveNewsRoom.com for MuGard, in addition to more information and links at the landing page

...

The cancer biotech space has attracted the interest of investors, traders, and diversified healthcare giants this year with Johnson & Johnson [JNJ: 55.50, +0.34 (+0.62%)] announcing a $1B cash tender offer for Cougar Biotech [CGRB: 42.87, -0.12 (-0.28%)] last week and Roche’s [ROG: 17.67, +0.61 (+3.58%)] [RHHBY: 0.00, N/A (N/A)] mega-deal to acquire full control of Genentech earlier this year. In addition, positive clinical trial results for Dendreon’s [DNDN: 23.2099, +0.5399 (+2.38%)] Provenge and stock price turnarounds from the brink of zero at Cell Therapeutics [CTIC: 1.60, +0.17 (+11.89%)] have fueled interest in the small and micro-cap cancer bio-pharma space among investors and traders looking for the next big trade.

Access Pharma [ACCP: 0.00, N/A (N/A)] is an emerging bio-pharma company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to

...

Following the market close on Thursday, Johnson & Johnson (JNJ) announced that it had signed a definitive agreement to acquire Cougar Biotechnology, Inc. (CGRB). J&J will initiate a tender offer to purchase all of the outstanding stock of Cougar at $43 per share ($893 million), a 16% premium over Thursday's closing price.The boards of both companies have approved the transaction, which is expected to close in the third quarter. J&J expects the deal to be dilutive to 2009 EPS by $0.02 - $0.03.As mentioned in our recent reports and blogs on Cougar Biotechnology, based on the significant potential of the company's lead candidate, we expected the company to attract a partner or suitor in the near-term. JNJ's pharmaceutical business has struggled lately due to a number of the company's blockbuster drugs experiencing declining sales due to generic competition or safety concerns.While ...

Fiscal 2009 third quarter financial performance remains strong Myriad Genetics, Inc. (MYGN) relies on its molecular diagnostic products for its revenue generation and is currently seeing solid growth in this business. On May 4, 2009, the company reported fiscal 3Q09 financial results ended March 31, 2009.Total revenue for the 2009 fiscal third quarter increased to a record $87.5 million, compared with $61.8 million in the prior-year period. Molecular diagnostic revenues rose 47% to $86.5 million from $59.0 million last year. The improvement resulted primarily from an increase in the Company's sales and marketing efforts, including expansion of its women's health sales force. It was also due to the continuation of its direct-to-consumer marketing campaign, which the company believes has resulted in improved physician acceptance and adoption of its molecular diagnostic products. Molecular diagnostic revenue of $86.5 million in 3Q09 was slightly lower than our ...